3 Promising Penny Stocks In The US With Market Caps Under $400M

As the U.S. stock market reaches record highs, with indices like the S&P 500 and Dow Jones posting their biggest monthly gains of 2024, investors are exploring opportunities beyond well-known large-cap stocks. Penny stocks, often representing smaller or newer companies, continue to intrigue investors despite their vintage name. This article will spotlight several penny stocks that stand out for their financial strength and potential for long-term success amidst current market conditions.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.80	$5.81M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.62	$2.03B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$136.98M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2408	$8.86M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.59	$52.47M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.81	$142.8M	★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9429	$84.8M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.87	$413.23M	★★★★☆☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Alpha Tau Medical (NasdaqCM:DRTS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid cancers in Israel and the United States, with a market cap of approximately $195.79 million.

Operations: There are no reported revenue segments for this clinical-stage oncology therapeutics company.

Market Cap: $195.79M

Alpha Tau Medical Ltd., a pre-revenue clinical-stage oncology company, is focused on advancing its Alpha DaRT technology for treating solid cancers. Despite reporting a net loss of US$22.27 million for the first nine months of 2024, the company has made significant strides in regulatory progress and clinical trials. It was accepted into the FDA's Total Product Life Cycle Advisory Program to expedite market access for its treatment targeting recurrent glioblastoma multiforme. Additionally, it initiated clinical trials for lung cancer and received FDA approval to study recurrent cutaneous Squamous Cell Carcinoma in immunocompromised patients, highlighting potential growth avenues.

• Unlock comprehensive insights into our analysis of Alpha Tau Medical stock in this financial health report.
• Examine Alpha Tau Medical's earnings growth report to understand how analysts expect it to perform.

BARK (NYSE:BARK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: BARK Inc. is a dog-centric company that offers products, services, and content for dogs with a market cap of $375.74 million.

Operations: The company's revenue is derived from two segments: Commerce, contributing $58.98 million, and Direct to Consumer, generating $429.91 million.

Market Cap: $375.74M

BARK Inc. is navigating the challenges of being unprofitable with strategic initiatives to bolster its market position. The company recently launched its BarkBox in retail via Target, aiming to expand its consumer reach during the holiday season. Despite reporting a net loss of US$5.26 million for Q2 2024, BARK's revenue slightly increased year-over-year to US$126.11 million, and it maintains a strong cash runway exceeding three years due to positive free cash flow. Additionally, BARK has been actively managing its capital structure by repurchasing shares and improving shareholder equity from negative levels five years ago.

• Take a closer look at BARK's potential here in our financial health report.
• Review our growth performance report to gain insights into BARK's future.

TuSimple Holdings (OTCPK:TSPH)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: TuSimple Holdings Inc. is an autonomous technology company focused on developing self-driving solutions for semi-trucks in the United States and Asia-Pacific region, with a market cap of approximately $93.05 million.

Operations: TuSimple Holdings Inc. has not reported any revenue segments.

Market Cap: $93.05M

TuSimple Holdings Inc. faces significant challenges as a pre-revenue company, reporting only US$0.307 million in sales for 2023 and a net loss of US$280.54 million. Despite having no debt and substantial short-term assets of US$743.5 million covering both its short- and long-term liabilities, the company's share price remains highly volatile with weekly volatility higher than most U.S. stocks. Recent investor activism highlights internal disagreements, with demands for full liquidation reflecting potential instability in governance due to an inexperienced board averaging 2.1 years tenure, which could impact future strategic direction or investor confidence.

• Jump into the full analysis health report here for a deeper understanding of TuSimple Holdings.
• Gain insights into TuSimple Holdings' historical outcomes by reviewing our past performance report.

Where To Now?

• Click here to access our complete index of 709 US Penny Stocks.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com